KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Assets (2020 - 2025)

Historic Assets for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $1.4 billion.

  • AbCellera Biologics' Assets fell 264.47% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 264.47%. This contributed to the annual value of $1.4 billion for FY2024, which is 857.08% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Assets is $1.4 billion, which was down 264.47% from $1.4 billion recorded in Q2 2025.
  • AbCellera Biologics' Assets' 5-year high stood at $1.6 billion during Q2 2022, with a 5-year trough of $1.1 billion in Q1 2021.
  • Moreover, its 5-year median value for Assets was $1.4 billion (2024), whereas its average is $1.4 billion.
  • Its Assets has fluctuated over the past 5 years, first soared by 4109.5% in 2022, then tumbled by 857.08% in 2024.
  • Over the past 5 years, AbCellera Biologics' Assets (Quarter) stood at $1.3 billion in 2021, then rose by 16.86% to $1.5 billion in 2022, then fell by 3.43% to $1.5 billion in 2023, then dropped by 8.57% to $1.4 billion in 2024, then decreased by 0.34% to $1.4 billion in 2025.
  • Its Assets stands at $1.4 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.3 billion for Q1 2025.